Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.
暂无分享，去创建一个
Shaji K. Kumar | D. Reece | J. Zeldis | R. Gams | R. Abonour | Christine I. Chen | D. Irwin | E. Stadtmauer | R. Knight | D. Pietronigro | D. Siegel | R. Niesvizky | Laurie Kenvin | R. Boccia | J. Polikoff | A. Hu | Dale McElveen